Source: Pharamceutical Technology

Coherus: Coherus divests Udenyca franchise to Intas for up to $558.4m

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals for up to $558.4m.

Read full article »
Coherus's Competitors | Coherus's News | Coherus's Financials
Stay up-to-date with the latest news on Coherus
Annual Revenue
$100-500M
Employees
100-250
Dennis M. Lanfear's photo - Chairman & CEO of Coherus

Chairman & CEO

Dennis M. Lanfear

CEO Approval Rating

40/100

Read more
Stay up-to-date with the latest news on Coherus